The ASTEROID trial: Coronary plaque regression with high-dose statin therapy

Adnan K. Chhatriwalla, Stephen J. Nicholls, Steven E. Nissen

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

A Study To Evaluate the effect of Rosuvastatin On Intravascular ultrasound-Derived coronary atheroma burden (ASTEROID) investigated the impact of high-dose rosuvastatin therapy on the rate of atheroma progression in patients with coronary artery disease. Serial intravascular ultrasound (IVUS) was performed in 349 patients at baseline and following 24 months of therapy with rosuvastatin 40 mg/day. Rosuvastatin therapy lowered low-density lipoprotein cholesterol to 60.8 mg/dl and raised high-density lipoprotein cholesterol by 14.7%. This was associated with a significant reduction in all IVUS measures of atheroma burden. These results suggest that intensive modification of lipid levels with high-dose statin therapy can promote atheroma regression. Further studies will be required to determine whether this benefit is associated with a reduction in clinical events.

LanguageEnglish
Pages651-654
Number of pages4
JournalFuture Cardiology
Volume2
Issue number6
DOIs
Publication statusPublished - 1 Nov 2006

Keywords

  • Atherosclerosis
  • Cholesterol
  • Coronary artery disease
  • HMG Co-A reductase inhibitors
  • Intravascular ultrasound
  • Low-density lipoprotein cholesterol
  • Statins

ASJC Scopus subject areas

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Chhatriwalla, Adnan K. ; Nicholls, Stephen J. ; Nissen, Steven E. / The ASTEROID trial : Coronary plaque regression with high-dose statin therapy. In: Future Cardiology. 2006 ; Vol. 2, No. 6. pp. 651-654.
@article{ed8c54cafd6e4d8091e8f018125398cc,
title = "The ASTEROID trial: Coronary plaque regression with high-dose statin therapy",
abstract = "A Study To Evaluate the effect of Rosuvastatin On Intravascular ultrasound-Derived coronary atheroma burden (ASTEROID) investigated the impact of high-dose rosuvastatin therapy on the rate of atheroma progression in patients with coronary artery disease. Serial intravascular ultrasound (IVUS) was performed in 349 patients at baseline and following 24 months of therapy with rosuvastatin 40 mg/day. Rosuvastatin therapy lowered low-density lipoprotein cholesterol to 60.8 mg/dl and raised high-density lipoprotein cholesterol by 14.7{\%}. This was associated with a significant reduction in all IVUS measures of atheroma burden. These results suggest that intensive modification of lipid levels with high-dose statin therapy can promote atheroma regression. Further studies will be required to determine whether this benefit is associated with a reduction in clinical events.",
keywords = "Atherosclerosis, Cholesterol, Coronary artery disease, HMG Co-A reductase inhibitors, Intravascular ultrasound, Low-density lipoprotein cholesterol, Statins",
author = "Chhatriwalla, {Adnan K.} and Nicholls, {Stephen J.} and Nissen, {Steven E.}",
year = "2006",
month = "11",
day = "1",
doi = "10.2217/14796678.2.6.651",
language = "English",
volume = "2",
pages = "651--654",
journal = "Future Cardiology",
issn = "1479-6678",
publisher = "Future Medicine Ltd.",
number = "6",

}

The ASTEROID trial : Coronary plaque regression with high-dose statin therapy. / Chhatriwalla, Adnan K.; Nicholls, Stephen J.; Nissen, Steven E.

In: Future Cardiology, Vol. 2, No. 6, 01.11.2006, p. 651-654.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The ASTEROID trial

T2 - Future Cardiology

AU - Chhatriwalla, Adnan K.

AU - Nicholls, Stephen J.

AU - Nissen, Steven E.

PY - 2006/11/1

Y1 - 2006/11/1

N2 - A Study To Evaluate the effect of Rosuvastatin On Intravascular ultrasound-Derived coronary atheroma burden (ASTEROID) investigated the impact of high-dose rosuvastatin therapy on the rate of atheroma progression in patients with coronary artery disease. Serial intravascular ultrasound (IVUS) was performed in 349 patients at baseline and following 24 months of therapy with rosuvastatin 40 mg/day. Rosuvastatin therapy lowered low-density lipoprotein cholesterol to 60.8 mg/dl and raised high-density lipoprotein cholesterol by 14.7%. This was associated with a significant reduction in all IVUS measures of atheroma burden. These results suggest that intensive modification of lipid levels with high-dose statin therapy can promote atheroma regression. Further studies will be required to determine whether this benefit is associated with a reduction in clinical events.

AB - A Study To Evaluate the effect of Rosuvastatin On Intravascular ultrasound-Derived coronary atheroma burden (ASTEROID) investigated the impact of high-dose rosuvastatin therapy on the rate of atheroma progression in patients with coronary artery disease. Serial intravascular ultrasound (IVUS) was performed in 349 patients at baseline and following 24 months of therapy with rosuvastatin 40 mg/day. Rosuvastatin therapy lowered low-density lipoprotein cholesterol to 60.8 mg/dl and raised high-density lipoprotein cholesterol by 14.7%. This was associated with a significant reduction in all IVUS measures of atheroma burden. These results suggest that intensive modification of lipid levels with high-dose statin therapy can promote atheroma regression. Further studies will be required to determine whether this benefit is associated with a reduction in clinical events.

KW - Atherosclerosis

KW - Cholesterol

KW - Coronary artery disease

KW - HMG Co-A reductase inhibitors

KW - Intravascular ultrasound

KW - Low-density lipoprotein cholesterol

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=33750975918&partnerID=8YFLogxK

U2 - 10.2217/14796678.2.6.651

DO - 10.2217/14796678.2.6.651

M3 - Article

VL - 2

SP - 651

EP - 654

JO - Future Cardiology

JF - Future Cardiology

SN - 1479-6678

IS - 6

ER -